RxDoctor Payments Data

James Shaffer, MD

Critical Care Medicine · Cookeville, TNNPI 1801859368

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 61.2% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $1,245, 4.2 times the $299 reported in 2019.

$1,823in general payments, 2019–2025

Across 38 payments — averaging $47.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • GSK$225
  • AstraZeneca$223
  • Intuitive Surgical$67
  • Sanofi$33
  • Insmed, Inc.$32
  • plus $126 from 6 others

What the payments were for

  • Travel & lodging$81445%
  • Food & beverage$97754%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,823 in reported general payments places this provider in the 70th percentile of 141 critical care medicine providers in Tennessee.

See all critical care medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$94,171
Medicare patients
341
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$55,283
Breo ElliptaFluticasone/Vilanterol21$9,299
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$7,248
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,249
Albuterol Sulfate HfaAlbuterol Sulfate118$3,444
Azelastine Hcl25$706
Doxycycline Hyclate63$466
Prednisone101$360
Azithromycin28$293
Fluticasone Propionate23$187
Doxycycline Monohydrate19$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$225$69,832107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 141 critical care medicine providers in Tennessee.

Other critical care medicine in Cookeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →